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Abstract 
Background: Bromelain, which is a cysteine endopeptidase commonly found in pineapple stems, has been inves-
tigated as a potential anti-cancer agent for the treatment of breast cancer. However, information pertaining to the 
effects of combining bromelain with existing chemotherapeutic drugs remains scarce. This study aimed to investigate 
the possible synergistic cytotoxic effects of using bromelain in combination with cisplatin on MDA-MB-231 human 
breast cancer cells.
Method: MDA-MB-231 cells were treated with different concentrations (0.24–9.5 µM) of bromelain or cisplatin alone, 
as well as four different combinations of these two agents to assess their individual and combination effects after 
24 and 48 h. Cell viability was analyzed using an MTT assay. The induction of apoptosis was assessed using cell cycle 
analysis and an Annexin V-FITC assay. The role of the mitochondrial membrane potential in the apoptotic process was 
assessed using a JC-1 staining assay. Apoptotic protein levels were assessed by western blot analysis and proteome 
profiling using an antibody array kit.
Results: Single-agent treatment with cisplatin or bromelain led to dose- and time-dependent decreases in the viabil-
ity of the MDA-MB-231 cells at 24 and 48 h. Furthermore, most of the combinations evaluated in this study displayed 
synergistic effects against MDA-MB-231 cells at 48 h, with combination 1 (bromelain 2 µM + cisplatin 1.5 µM) exhibit-
ing the greatest synergistic effect (P = 0.000). The results of subsequent assays indicated that combination 1 treat-
ment induced apoptosis via mitochondria-mediated pathway. Combination 1 also resulted in significant decreases 
in the levels of several apoptotic proteins such as Bcl-x and HSP70, compared with bromelain (P = 0.002 and 0.000, 
respectively) or cisplatin (P = 0.000 and 0.001, respectively) single treatment. Notably, MDA-MB-231 cells treated with 
combination 1 showed increased levels of the pro-apoptotic proteins Bax compared with those treated with bro-
melain (P = 0.000) or cisplatin single treatment (P = 0.043).
Conclusion: Bromelain in combination with cisplatin synergistically enhanced the induction of apoptosis in MDA-
MB-231 cells.
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Background
Breast cancer is the most frequently diagnosed invasive 
non-skin malignancy and the leading cause of cancer-
related deaths in women throughout the world [1]. In 
Asia, the incidence and mortality rates of breast cancer 
have been steadily rising for several years, with unhealthy 
diet, physical inactivity and obesity being identified as the 
main contributing factors [2]. Although there are many 
different strategies available for the clinical treatment of 
breast cancer, the effectiveness of these approaches can 
be limited by the occurrence of adverse side effects and 
the development of drug resistance.
cis-Diamminedichloroplatinum (CDDP), which is 
more commonly known as cisplatin, is one of the most 
effective anti-cancer agents currently used in clinical 
practice, with pronounced activity against various can-
cers, including breast cancer [3, 4]. Cisplatin interacts 
with DNA and interferes with the mechanisms respon-
sible for its transcription and replication [5, 6]. Conse-
quently, cisplatin treatment is associated with a number 
of serious side effects such as nephrotoxicity, myelosup-
pression, ototoxicity, anaphylactic reactions, peripheral 
neuropathies and hypomagnesemia [7–9]. Furthermore, 
the clinical application of cisplatin is limited by the devel-
opment of resistance mechanisms in the cancer cells [10–
12]. The combination of cisplatin with other anti-cancer 
agents that operate via a different mode of action could 
therefore be used as an effective strategy to impede the 
growth of human cancer cells that develop resistance to 
cisplatin. This strategy could also minimize the severity 
of the side effects associated with the individual agents, 
whilst maintaining or even enhancing the effectiveness of 
the treatment process.
Pineapple (Ananascomosus L.) has been used to treat 
a wide range of diseases in several different countries, 
including Thailand, Malaysia, Taiwan and China, as well 
as the state of Hawaii [13]. Pineapple plants are com-
monly used in folk medicine, especially their crown 
leaves, which are used to treat open wounds and inflam-
mation. The results of a previous study demonstrated that 
pineapple crown leaf extract exhibited several interest-
ing biological properties, including antimicrobial, anti-
edema and anti-inflammatory activities [14].Pineapple 
stems have also been reported to exhibit a broad range of 
promising pharmacological properties. Stem bromelain 
is a cysteine endopeptidase, which is commonly found 
at a high concentration in the crude extract of pineap-
ple stems (Ananascomosus L.) [15]. The results of several 
in  vitro and in  vivo studies [16–21] have demonstrated 
that bromelain exhibited various beneficial therapeu-
tic effects, including anti-tumor activity. These results 
therefore support the potential application of stem bro-
melain as a therapeutic agent for the treatment of cancer. 
Moreover, bromelain exhibits good stability over a wide 
range of pH values [22, 23] and is readily adsorbed in the 
human intestinal tract in its functional active form when 
it is consumed in high concentrations (up to 12  g/day). 
Taken together with the fact that its consumption does 
not lead to any major side effects, these results further 
highlight the potential of bromelain as an anti-cancer 
agent [24, 25].
The study aimed to investigate the possible synergis-
tic cytotoxic effects of using bromelain in combination 




Unless specified otherwise, all of the chemicals used 
in this study, including bromelain and cisplatin, were 
obtained from Sigma Aldrich (St Louis, MO, USA). Stock 
solutions of bromelain in water were freshly prepared 
prior to each experiment using deionized water. The 
resulting aqueous solutions were filtered (0.2  µm) prior 
to being used in the experiments. A stock solution of cis-
platin was prepared in the dark using deionized water 
containing 0.9% (w/w) sodium chloride. The resulting 
stock solution was stored at 4  °C in the absence of light 
prior to being used.
Cell cultures
The MDA-MB-231 cells used in this study obtained from 
the American Type Culture Collection (Rockville, MD, 
USA). The cells were cultured in Roswell Park Memorial 
Institute medium enriched with 10% fetal bovine serum 
and 100  units/mL penicillin–streptomycin antibiotic at 
37 °C under a humidified atmosphere containing 5% CO2.
MTT assay
Cell growth inhibition was determined using a colori-
metric MTT assay. The assay was conducted in a 96-well 
plate with a cell density of 8  ×  103  cells per well with 
an incubation period of 24  h. The medium was subse-
quently removed and replaced with fresh medium con-
taining the test compound, followed by an incubation 
period of 24 or 48 h. The cells were then incubated with 
MTT solution (0.5  mg/mL) for 4  h, and the resulting 
formazan precipitate was dissolved in 170 µL of DMSO. 
The absorbance of each well was then measured at 
570  nm using a microplate spectrophotometer (Bio-Tek 
Instruments, Winooski, VT, USA). The percentage of 
cell survival was calculated using the following formula: 
percentage (%) cell survival = [(mean absorbency in test 
wells)/(mean absorbency in control wells)] × 100. These 
experiments were conducted in triplicate. We then con-
structed a graph of the percentage cell viability against 
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the concentration of the test compound. The resulting 
graph was used to determine the IC10, IC20, IC30, IC40 
and IC50 values of bromelain and cisplatin for the single 
treatment of the MDA-MB-231 cells.
We also conducted a series of MTT assays using four 
different combinations of bromelain and cisplatin (i.e., 
IC40 bromelain + IC10 cisplatin, IC30 bromelain + IC20 
cisplatin, IC20 bromelain +  IC30 cisplatin and IC10 bro-
melain + IC40 cisplatin) with concentrations in the range 
of 0.24–9.5  µM. All of these assays were conducted in a 
96-well plate with a cell density of 8 ×  103 cells per well 
with an incubation period of 24 h. The medium was subse-
quently removed and replaced with fresh medium contain-
ing the test compound, followed by an incubation period 
of 48 h. The cells were then incubated with MTT solution 
(0.5 mg/mL) for 4 h, and the resulting formazan precipi-
tate was dissolved in 170 µL of DMSO. The absorbance of 
each well was then measured at 570 nm using a microplate 
spectrophotometer (Bio-Tek Instruments). All of these 
experiments were conducted independently in triplicate.
Annexin V‑FITC assay
The cells were seeded into a 6-well plate and incubated 
for 24 h at 37 °C under a humidified atmosphere contain-
ing 5% CO2. The medium in each well was subsequently 
replaced with fresh medium containing different con-
centrations of the test compounds. After an incubation 
period of 24 or 48 h, all of the detached/dead and viable 
cells were collected. The cells were then washed and 
resuspended with PBS. The harvested cells were stained 
with Annexin V for 30 min before being treated with PI 
and analyzed by flow cytometry using a FACScan sys-
tem (Becton–Dickinson and Company, San Jose, CA, 
USA) equipped with version 3.3 of the CellQuest soft-
ware (Becton–Dickinson and Company). This assay was 
conducted according to the manufacturer’s protocol (BD 
PharmingenAnnexin V-FITC Apoptosis Detection Kit 1).
Measurement of mitochondrial membrane potential (JC‑1 
staining assay)
The cells were seeded into a 6-well plate and incubated 
for 24 h at 37 °C under a humidified atmosphere contain-
ing 5% CO2. The medium in each well was then replaced 
with fresh medium containing different concentrations of 
the test compounds. After an incubation period of 48 h, 
all the detached/dead and viable cells were harvested, 
washed with PBS and incubated with culture medium 
containing JC-1 for 30  min at 37  °C in the absence of 
light. The cells were then washed twice with PBS, resus-
pended in 500  µL of PBS and immediately analyzed by 
flow cytometry using a FACScan system (Becton–Dick-
inson and Company) equipped version 3.3 of the Cell-
Quest software.
Cell cycle analysis
The cells were seeded into a 6-well plate and incubated 
for 24 h at 37 °C under a humidified atmosphere contain-
ing 5% CO2. The medium in each well was then replaced 
with fresh medium containing different concentrations of 
the test compounds. After an incubation period of 24 or 
48 h, all of the detached/dead and viable cells were col-
lected, washed with cold PBS and resuspended in 50 mL 
of cold PBS before being treated with 450  µL of cold 
ethanol. The cells were then incubated for 24 h at 4  °C. 
At the end of the incubation period, the cells were centri-
fuged (Model 5804 R, Eppendorf, Hamburg, Germany) at 
200×g for 5 min and the resulting pellet was washed with 
cold PBS and resuspended in 500  µL of PBS. The cells 
were then incubated with 5 µL of RNase (20 μg/mL final 
concentration) for 30 min before being incubated with PI 
(50  µg/mL) on ice for 1  h in the dark. The distribution 
of cells was then immediately analyzed by flow cytom-
etry using a FACScan system (Becton–Dickinson and 
Company) equipped with version 3.3 of the CellQuest 
software.
Proteome Profiler™: human apoptosis array
The cells were seeded in a 6-well plate and incubated for 
24 h at 37 °C under a humidified atmosphere containing 
5% CO2. The medium in each well was then replaced with 
fresh medium containing different concentrations of the 
test compounds. After an incubation period of 48 h, the 
cells were washed with PBS and lysed. All of the immu-
nodetection steps were performed using a Proteome 
Profiler Human Apoptosis Array Kit (R&D Systems, 
Minneapolis, MN, USA) in accordance with the manu-
facturer’s instructions. Briefly, the array was washed and 
incubated with a mixture of biotinylated detection anti-
bodies. Streptavidin-HRP and chemiluminescent detec-
tion reagents were used, and a signal corresponding to 
the amount of protein bound was produced on each cap-
ture spot. After incubation, the membranes were devel-
oped using enhanced chemiluminescence reagents and 
immediately viewed and analyzed using a ChemiDoc 
XRS  +  system (Bio-Rad, Hercules, CA, USA). Protein 
expression was normalized to a positive control, which 
was present in each membrane.
Western blot
The cells were seeded into a 6-well plate and incubated 
for 24 h at 37 °C under a humidified atmosphere contain-
ing 5% CO2. The medium in each well was then replaced 
with fresh medium containing different concentrations 
of the test compound. Following an incubation period of 
24 or 48 h, the cells were washed with PBS and lysed in 
RIPA lysis buffer [50 mM Hepes (pH 7.5), 150 mM NaCl, 
1% deoxycholate, 1% NP-40, 0.1% sodium dodecyl sulfate 
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(SDS)] containing protease inhibitors (Thermo Fisher 
Scientific, Waltham, MA, USA). The extracted proteins 
(20–60  µg) were separated by electrophoresis on SDS–
polyacrylamide gels, transferred to nitrocellulose mem-
branes (Bio-Rad) and probed with respective primary 
antibodies against Beta-actin, Bax and Bcl-2 (Abcam, 
Cambridge, Massachusetts, USA). After being incubated 
with the corresponding secondary antibodies (Abcam, 
the immunoreacted proteins were detected using a 
chemiluminescence system (ECL Western blot substrate; 
Abcam, Cambridge, UK).The bands obtained were quan-
titated using the ImageJ software (Bio Techniques, New 
York, NY, USA).
Statistical analysis
All of the experiments described in this study were 
repeated independently for at least three times (n =  3) 
and measured in triplicate, unless specified otherwise. 
The results have been reported as the corresponding 
mean values ±  standard deviation (SD). Statistical data 
for MTT assay, Annexin-V/FitC assay, JC-1 staining assay 
and cell cycle analysis was analyzed by the Student’s t test 
and one-way analysis of variance (ANOVA), followed 
by Tukey’s multiple comparison post hoc test. Statistical 
analyses were performed using version 19 of the SPSS 
software for Windows (IBM SPSS, Chicago, IL, USA). 
Differences between the experimental groups were con-
sidered significant for P values of less than 0.05. Data 
analyses to determine the CI value of the combination 
treatment used were performed using the CompuSyn 
software (Combo SynInc, City, State, USA). CI < 1 indi-
cates synergism, CI  =  1 indicates additive effect, and 
CI > 1 indicates antagonism.
Results
Inhibitory effects of cisplatin and bromelain (single‑agent 
and combined treatment) on the growth of MDA‑MB‑231 
cells
The proliferation of MDA-MB-231 cells was assessed 
using an MTT assay. The assay was conducted in the 
presence of various concentrations of cisplatin or bro-
melain, as well as different combinations of these two 
agents over 24 and 48  h to explore their effects on the 
MDA-MB-231 cells. The treatment of the cells with cispl-
atin or bromelain alone resulted in a dose-dependent and 
a time-dependent decrease in the viability of the MDA-
MB-231 cells at 24 and 48 h, with higher concentrations 
and longer treatment times resulting in lower levels of 
cell viability (Fig. 1).
These results were used to determine the concen-
trations of cisplatin and bromelain required to inhibit 
the growth of the MDA-MB-231 cells by 50, 40, 30, 
20 and 10% (i.e., the IC50, IC40, IC30, IC20 and IC10 
values) at 48 h. Based on these values, we were able to 
combine these concentrations into four different com-
binations of cisplatin and bromelain, which were sub-
sequently tested against MDA-MB-231 cells for 48  h. 
The results of these combination studies are shown in 
Table  1. Combination 1 (bromelain 2  µM  +  cisplatin 
1.5 µM) induced the greatest reduction in cell viability 
compared to combination 2 (P = 0.000), combination 3 
(P = 0.000) and combination 4 (P = 0.000), indicating 
that it exhibited the strongest inhibitory effect of the 
four combinations.
Synergistic effects of combinations of cisplatin 
and bromelain for the treatment of MDA‑MB‑231 cells
The CI and DRI values, as well as the isobolograms for all 
of the bromelain and cisplatin combinations, are shown in 
Table 2. Only combinations 1, 3 and 4 gave CI values of less 
than 1, with combination 1 showing the lowest CI value 















































Fig. 1 Dose- and time-dependent inhibition of viability in MDA-
MB-231 cells by bromelain and cisplatin single treatment. The figure 
shown in a is the MTT assay results for bromelain at 24 and 48 h, with 
IC50 value for bromelain at 48 h is 4.10 µM. The figure shown in b is 
the MTT assay results for cisplatin at 24 and 48 h, with IC50 value for 
cisplatin at 48 h is 23.0 µM. The results are expressed as mean ± SD of 
three separate experiments
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0.65). The results of the isobolograms were consistent with 
those of the CI values and revealed the presence of syner-
gistic effects for combinations 1, 3 and 4 at 48 h (Fig. 2). 
The DRI values also supported the presence of synergistic 
effects, especially for combination 1, which had the high-
est DRI value for cisplatin. The DRI values showed that the 
IC50 dose of cisplatin could be reduced 13-fold when it 
was used in combination with bromelain in combination 
1. These results indicated that combination 1 showed the 
best synergistic effects of all of the combinations tested in 
this study at 48 h. This combination was therefore selected 
for the subsequent experiments.
Regulation of apoptosis and cell cycle progression 
in MDA‑MB‑231 cells by bromelain, cisplatin and their 
combined treatment
Annexin-V/PI and cell cycle analyses were performed on 
the MDA-MB-231 cells treated with combination 1 to 
determine whether the growth inhibitory effects of this 
treatment could be attributed to apoptosis or cell cycle 
arrest. The result of the Annexin-V/PI assay showed 
that the single-agent treatment of the MDA-MB-231 
cells with bromelain (4.1  µM) or cisplatin (23  µM) 
caused 31.68 and 31.07% of the cells to enter apoptosis 
at 48 h, respectively (Fig. 3). However, the treatment of 
MDA-MB-231 cells with combination 1 led to a marked 
increase in the population of apoptotic cells observed 
at 48  h to 40.69%. These results correlated well with 
the fraction of cells observed in sub-G0/G1 phase by 
cell cycle analysis (Fig.  4). The treatment of the MDA-
MB-231 cells with combination 1 led to a higher level 
of sub-G0/G1 arrest, with 15.94% of the cells being 
detected in the sub-G0/G1 phase, compared with val-
ues of 13.38 and 13.83% for single-agent treatment with 
bromelain (P = 0.000) and cisplatin (P = 0.000), respec-
tively. Single-agent treatment with bromelain and cispl-
atin, as well as combination treatment with combination 
1, induced apoptosis in MDA-MB-231 cells, with the 
former inducing higher levels of apoptosis than either of 
the single-agent treatments.
Table 1 Viability percentage of MDA-MB-231 at 48 h treated with bromelain and cisplatin combinations
Cytotoxicity was determined using the MTT cell viability assay. The results for MTT assay are expressed as mean ± SD of three separate experiments
Combination no. Combination dosage (µM) % viability ± SD
Bromelain dosage (IC value) Cisplatin dosage (IC value)
Combination 1 2.0 µM (IC40) 1.5 µM (IC10) 50.24% ± 1.67
Combination 2 0.9 µM (IC30) 4.0 µM (IC20) 70.26% ± 2.66
Combination 3 0.5 µM (IC20) 5.9 µM (IC30) 61.30% ± 2.43
Combination 4 0.24 µM (IC10) 9.5 µM (IC40) 56.95% ± 3.61
Table 2 Combination index (CI) and dose reduction index (DRI) values at 48 h for bromelain and cisplatin combinations. 
CI < 1 indicates synergistic effect, CI = 1 indicates additive effects and CI > 1 indicates antagonistic effect
Combination no. Combination dosage (µM) CI value DRI (bromelain) DRI (cisplatin)
Bromelain dosage (IC value) Cisplatin dosage (IC value)
Combination 1 2.0 µM (IC40) 1.5 µM (IC10) 0.65 1.74 12.71
Combination 2 0.9 µM (IC30) 4.0 µM (IC20) 1.36 1.27 1.73
Combination 3 0.5 µM (IC20) 5.9 µM (IC30) 0.78 3.87 1.89


















Fig. 2 Normalized isobologram plot of bromelain/cisplatin combina-
tions treatment on MDA-MB-231 cells at 48 h
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Activation of apoptosis via an intrinsic (mitochondrial) 
pathway in MDA‑MB‑231 cells treated with a combination 
of bromelain and cisplatin
A JC-1 staining assay was used to measure changes in 
the mitochondrial membrane potentials of the MDA-
MB-231 cells subjected to the single-agent and combi-
nation treatments. As shown in Fig.  5, the percentages 
of cells determined to be positive for JC-1 monomers 
following their single-agent treatment with bromelain 
(4.1 µM) and cisplatin (23 µM) for 48 h were 41.82% and 
51.40%, respectively. For combination 1, the percent-
age of cells found to be positive for JC-1 monomers was 
40.58%. These values were significantly higher than that 
found in the untreated control, where only 9.33% of the 
cells tested positive for JC-1 monomers (P = 0.000). The 
mitochondrial membrane potentials of the treated cells 
decreased, suggesting that the treatment of the cells with 
either of the single agents or combination 1 triggered 
apoptosis via the induction of the intrinsic (mitochon-
drial) pathway.
Modulatory effects of bromelain and cisplatin alone, 
as well as a combination of these two agents on the 
expression levels of apoptosis‑related proteins
A number of apoptotic proteins, including Bcl-2, cata-
lase, clusterin, HO-1, livin, XIAP, HSP70, Bcl-x, Bax and 
HSP60 were differentially expressed in the treated and 





























































































































































Fig. 3 FITC-Annexin V/PI and propidium iodide staining of MDA-MB-231 cells treated with bromelain, cisplatin and bromelain/cisplatin combina-
tion for 24 and 48 h. The results are expressed as mean ± SD of three separate experiments. The figures shown in a are results from one of the 
three experiments conducted. The x-axis (Annexin-V/FITC) and y-axis (propidiumiodide) represent the intensity of Annexin-V/FITC and propidium 
iodide staining in cells, respectively. Shown in b and c are the analyzed results for 24 and 48 h, respectively. The numerical data are presented as 
mean ± SD (n = 3). *P < 0.05 vs. Control
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The expression levels of Bcl-2 protein were found to 
be significantly reduced in the combination 1-treated 
cells compared with the bromelain- (P  =  0.002) and 
untreated cells (P = 0.001). The expression level of Livin, 
Bax, Catalase, HO-1 and XIAP were also found to be 
significantly reduced in the combination 1-treated cells 
compared with the bromelain- (P = 0.000) and untreated 
cells (P = 0.000). However, the expression levels of sev-
eral anti-apoptotic proteins, including HSP70 increased 
significantly in the MDA-MB-231 cells treated with com-
bination 1 compared with the bromelain- (P  =  0.016) 
and cisplatin-treated cells (P  =  0.001). Moreover, the 
expression level of Bcl-x were also found to significantly 
higher in the combination 1-treated cells compared with 
the bromelain- (P  =  0.002) and cisplatin-treated cells 
(P  =  0.000).The expression levels of pro-apoptotic pro-
teins HSP60 were found to be significantly reduced in the 
cells treated with combination 1 compared with the bro-
melain- (P = 0.041) and untreated cells (P = 0.014).
These results indicated that combination 1 affected 
the expression levels of most of the apoptotic proteins in 
MDA-MB-231 to a much greater extent than single-agent 
treatment with bromelain (4.1 µM) or cisplatin (23 µM). 
These results were therefore consistent with those of the 
JC-1 staining assay, with the fold-change values for Bax 
to Bcl-x and Bax to Bcl-2 suggesting the involvement of 
the mitochondrial pathway in the apoptosis induced by 
































































































































Fig. 4 Effect of bromelain, cisplatin and bromelain/cisplatin combination treatment on MDA-MB-231 cell cycle after 24 and 48 h. The figures shown 
in a are the results from one of the three experiments conducted. Data shown represent relative numbers of cells (Y-axis) vs. DNA content (X-axis). 
Shown in b and c are the analyzed cell cycle results for 24 and 48 h respectively. The numerical data are presented as mean ± SD (n = 3). *P < 0.05 
vs. Control
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1. The ratios of Bax to Bcl-2 and Bax to Bcl-x were cal-
culated and the results are shown in Fig. 7. These results 
revealed that was an increase in the Bax/Bcl-2 ratio 
following the treatment of the cells with combination 1, 









































Fig. 5 Effect of bromelain, cisplatin and bromelain/cisplatin combination after 48 h treatment duration on mitochondrial membrane potential in 
MDA-MB-231 cells as measured by JC-1 staining. The figures shown in a are the results from one of the three experiments conducted. Locations of 
R1 region (cells population with normal mitochondrial potential) and R2 region (cells population with reduced mitochondrial potential) are marked 
for each plot. Shown in b are the percentages of cells positive for JC-1 monomers for the treated and untreated MDA-MB-231 cells. The numerical 



















Fig. 6 Alterations of apoptosis-related proteins by bromelain, cisplatin and bromelain/cisplatin combination treatment at 48 h. Shown here are the 
fold-change values for the pixel density of selected apoptotic proteins of treated cells to untreated cells (control) at 48 h, obtained using Proteome 
Profiler: human apoptosis array (R&D System). The numerical data are presented as means of duplicate experiments (n = 3)
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To validate the results obtained using the Proteome 
Profiler Human Apoptosis Array kit, we also examined 
the protein extracts obtained from the MDA-MB231 
cells at 48  h by western blot analysis using anti-Beta-
actin, anti-Bcl-2 and anti-Bax (Fig. 8). The results of this 
analysis showed that the MDA-MB-231 cells treated with 
combination 1 contained much lower levels of the anti-
apoptotic protein Bcl-2 compared with the untreated 
cells (P  =  0.000), as well as the bromelain-treated 
(P  =  0.000) and cisplatin-treated cells (P  =  0.000). By 
contrast, we observed a higher level of the pro-apoptotic 
protein Bax after 48  h following the treatment of the 
cells with combination 1 compared with the control cells 
(P = 0.009), bromelain-treated cells (P = 0.002) and cispl-
atin-treated cells (P = 0.043). The results of this western 
blot analysis therefore suggested that the treatment of the 
cells with combination 1 led to a much greater decrease 
in the expression of Bcl-2 compared with single-agent 
treatment with bromelain or cisplatin. Furthermore, the 
observed increase in the expression of Bax highlights the 
importance of the role played by the mitochondrial path-
way in the apoptosis of the MDA-MB-231 cells triggered 
by combination 1.
Discussion
It was envisaged that the combination of bromelain and 
cisplatin would lead to synergistic effects, which would 
enhance their anti-cancer effects towards MDA-MB-231 
human breast cancer cells. The CI values and isobolo-
grams obtained using the MTT data clearly showed that 
the treatment of the MDA-MB-231 cells with a combina-
tion of bromelain and cisplatin resulted in a synergistic 
and dose-dependent increase in the inhibitory activity 
for combination 1 (bromelain 2 µM + cisplatin 1.5 µM) 
towards the growth of these cells. We also demonstrated 
that the IC50 dose of cisplatin was reduced almost 
13-fold in combination 1. Cisplatin is a well-known anti-
cancer agent, which is used in clinical practice to treat a 
variety of different cancers. However, despite its effec-
tiveness and broad range of activity, the use of cisplatin 
is associated with several adverse side effects [3, 4, 7–9]. 
In contrast, the cysteine endopeptidase bromelain is a 
non-toxic agent with proven anti-cancer activity against 
various cancers [17, 24]. The concentration ratio of bro-
melain to cisplatin played an important role in determin-
ing the extent of the synergistic effects, as exemplified 
by the differences observed for different concentrations 
of cisplatin and bromelain in the different combinations 
evaluated in this study.
Annexin V-FITC and cell cycle analyses were per-
formed on the treated and untreated MDA-MB-231 
cells to determine whether the growth inhibitory effects 
of combination 1 could be attributed to apoptosis. The 
results of these assays showed that the synergistic effects 
of combination 1 were caused by an augmented apoptotic 
response. This effect could also be attributed to a differ-
ent mode of action to those employed by cisplatin and 
bromelain. Cisplatin exerts its activity through the for-
mation of intra- and inter-strand DNA adducts that dam-
age the DNA and interferes with its normal functions 
[6, 26]. In contrast, the inhibitory effects of bromelain 
are dependent on its proteolytic activity, which allow it 
to remove certain cell surface molecules associated with 
cellular migration and adherence [27]. The proteolytic 
activity of bromelain has also been reported to promote 
apoptosis in a number of human cancer cells, particularly 
in breast cancer cells [18, 28].
Consistent with our results, previous studies have dem-



















Fig. 7 Fold-change values for Bax to Bcl-x and Bax to Bcl-2 in treated 











Fig. 8 Combination 1 (bromelain (2.0 µM) + cisplatin (1.5 µM)) 
decreased Bcl-2 protein expression and upregulated Bax protein 
expression. Shown here are the western blot gel images for Bcl-2, Bax 
and Beta-actin 35 at 48 h
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in the apoptosis induced by single-agent treatment with 
cisplatin or bromelain in cancer cells [28–31]. The treat-
ment of the MDA-MB-231 cells with combination 1 
resulted in a loss of mitochondrial membrane potential, 
which suggested that the mitochondrial pathway was 
involved in the apoptosis induced by combination 1.
The results obtained using the Proteome Profiler 
Human Apoptosis Array kit showed that combination 1 
led to decreases in the expression levels of several anti-
apoptotic proteins, including cIAP 1, Bcl-2, catalase, 
clusterin, HO-1, livin, XIAP, HSP27 and claspin. Nota-
bly, combination 1 led to considerable decreases in the 
expression levels of cIAP1, catalase, clusterin, HO-1, 
livin and XIAP compared with the cells treated with 
bromelain or cisplatin. Interestingly, we also observed 
pronounced increases in the expression levels of sev-
eral anti-apoptotic proteins, including HSP70 and Bcl-x 
in the cells treated with combination 1 compared with 
the untreated cells. In contrast, we did not observe any 
increases in the regulation of any pro-apoptotic proteins 
(e.g., Bax). We also observed an increase in the expres-
sion of the apoptotic protein HSP60.
Taken together with the observed decreases in the 
anti-apoptotic proteins Bcl-2 and HSP27, the increase 
observed in the pro-apoptotic protein Bax provided 
clear evidence that combination 1 induced mitochon-
dria-mediated apoptosis. This result was consistent 
with previous studies, which established the important 
roles played by Bcl-2, HSP27 and Bax in the regulation 
of apoptosis activated through the mitochondrial path-
way [32–38]. We also observed significant increases 
in the levels of the anti-apoptotic proteins HSP70 and 
Bcl-x in the cells treated with combination 1. Bcl-x and 
HSP70 play essential roles as anti-apoptotic proteins by 
preventing the release of mitochondrial apoptogenic fac-
tors such as cytochrome C and apoptosis inducing factor 
(AIF), and consequently inhibit apoptosis [36, 39]. The 
elevated levels of Bcl-x and HSP70 observed in this study 
would be insufficient to shut down the apoptotic process 
induced by combination 1 in MDA-MB-231 cells. The 
fold-change values shown in Fig. 6 for the pro-apoptotic 
protein Bax to the anti-apoptotic protein Bcl-x indicated 
that the increase in Bax was much greater than that of 
Bcl-x, suggesting that the pro-apoptotic effects of upreg-
ulated Bax would overwhelm the anti-apoptotic effects of 
Bcl-x. It is therefore possible that some other pathway or 
mechanism was being activated or inhibited by combi-
nation 1 and that this process was compensating for the 
interference in mitochondrial mediated-apoptosis and 
contributing to the synergistic effect of combination 1.
We also observed pronounced decreases in the levels of 
the anti-apoptotic proteins cIAP 1 and XIAP in the com-
bination 1-treated cells. This change was attributed to an 
increase in the expression of HSP70. Although HSP70 is 
well known for its cytoprotective effects, previous stud-
ies [40, 41] have also shown that elevated levels of HSP70 
may have led to an increased susceptibility to apoptosis. 
Elevated HSP70 levels would result in an increase in the 
inhibition of IkB kinase activity, which would inhibit the 
activity of the NF-kB pathway, leading to the inhibition 
of NF-kB-dependent anti-apoptotic gene induction [40–
42]. Given that the expression levels of cIAP and XIAP 
are highly dependent on the NF-kB pathway, the inhibi-
tion of the IkB kinase by elevated levels of HSP70 would 
lead to a reduction in the expression levels of cIAP and 
XIAP. This change could therefore explain the consider-
able decrease observed in the levels of cIAP and XIAP in 
this study.
Conclusion
Bromelain in combination with cisplatin synergistically 
enhanced the induction of apoptosis in MDA-MB-231 
cells.
Authors’ contributions
SKY, NBA, TS, NA, ARO, SAA and ALTC conceived and designed the study. 
AZMP, SKY and KLL performed the assays. AZMP, NA and SGT wrote the manu-
script. All authors read and approved to the final manuscript.
Author details
1 Department of Cell and Molecular Biology, Faculty of Biotechnology 
and Biomolecular Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, 
Malaysia. 2 Institute of Bioscience, Universiti Putra Malaysia, Serdang, Malaysia. 
3 Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rah-
man, Sungai Long Campus, Jalan Sungai Long, Bandar Sungai Long, Cheras, 
43000 Kajang, Selangor, Malaysia. 4 Department of Bioprocess Technology, 
Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, 
Serdang, Selangor, Malaysia. 
Acknowledgements
This research was supported by Research University Grant Scheme (Project No: 
05-02-12-1718RU) provided by Universiti Putra Malaysia, Malaysia.
Competing interests
The authors declare that they have no competing interests.
Received: 13 September 2016   Accepted: 4 November 2016
References
 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 
2010;127:2893–917.
 2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer 
incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev. 
2010;19:1893–907.
 3. Fuertes MA, Castilla J, Alonso C, Prez JM. Cisplatin biochemical mecha-
nism of action: from cytotoxicity to induction of cell death through 
interconnections between apoptotic and necrotic pathways. Curr Med 
Chem. 2003;10:257–66.
 4. Sledge GW, Loehrer PJ, Roth BJ, Einhorn LH. Cisplatin as first-line therapy 
for metastatic breast cancer. J Clin Oncol. 1988;6:1811–4.
 5. Marchán V, Moreno V, Pedroso E, Grandas A. Towards a better under-
standing of the cisplatin mode of action. Chem Eur J. 2001;7:808–15.
Page 11 of 11Pauzi et al. Chin Med  (2016) 11:46 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 6. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of 
resistance. Oncogene. 2003;22:7265–79.
 7. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young 
RC, Muggia FM. Toxic effects of cis-dichlorodiammineplatinum (II) in man. 
Cancer Treat Rep. 1979;63:1527–31.
 8. Laurell G, Jungnelius U. High-Dose cisplatin treatment: hearing loss and 
plasma concentrations. The Laryngoscope. 1990;100:724–34.
 9. Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, 
Stewart DJ. Cisplatin neurotoxicity: the relationship between dosage, 
time, and platinum concentration in neurologic tissues, and morphologic 
evidence of toxicity. J Clin Oncol. 1992;10:795–803.
 10. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, 
Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 
2012;31:1869–83.
 11. Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack 
MU, Gazdar AF, Minna JD, Royer HD. Epidermal growth factor receptor 
pathway analysis identifies amphiregulin as a key factor for cisplatin 
resistance of human breast cancer cells. J Bio Chem. 2008;283:739–50.
 12. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Koval-
chuk O. Alterations of microRNAs and their targets are associated with 
acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 
2010;127:1785–94.
 13. Xie W, Xing D, Sun H, Wang W, Ding Y, Du L. The effects of Ananascomosus 
L. Leaves on diabetic-dyslipidemic rats induced by alloxan and a high-fat/
high-cholesterol diet. Am J Chin Med. 2005;33:95–105.
 14. Dutta S, Bhattacharyya D. Enzymatic, antimicrobial and toxicity studies of 
the aqueous extract of Ananascomosus (pineapple) crown leaf. J Ethnop-
harmacol. 2013;150:451–7.
 15. Heinecke RM, Gortner WA. Stem bromelain, a new protease preparation 
from pineapple plants. Econ Bot. 1957;11:225–34.
 16. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple 
(Ananascomosus) and its clinical application. An update. J Ethnopharma-
col. 1988;22:191–203.
 17. Batkin S, Taussig SJ, Szekerczes J. Inhibition of tumour growth in vitro by 
bromelain, an extract of the pineapple (Ananascomosus). Plantamedica. 
1985;6:538–9.
 18. Dhandayuthapani S, Perez HD, Paroulek A, Chinnakkannu P, Kandalam U, 
Jaffe M, Rathinavelu A. Bromelain-induced apoptosis in GI-101A breast 
cancer cells. J Med Food. 2012;15:344–9.
 19. Batkin S, Taussig S, Szekerczes J. Modulation of pulmonary metastasis 
(Lewis lung carcinoma) by bromelain, an extract of the pineapple stem 
(Ananascomosus). Cancer Invest. 1988;6:241–2.
 20. Eckert K, Grabowska E, Stange R, Schneider U, Eschmann K, Maurer HR. 
Effects of oral bromelain administration on the impaired immunocyto-
toxicity of mononuclear cells from mammary tumor patients. Oncol Rep. 
1999;6:1191–200.
 21. Beuth J, Braun JM. Modulation of murine tumor growth and colonization 
by bromelaine, an extract of the pineapple plant (Ananascomosum L.). 
In Vivo. 2005;19:483–5.
 22. Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell 
Mol Life Sci. 2001;58:1231–45.
 23. Hale LP, Greer PK, Trinh CT, James CL. Proteinase activity and stabil-
ity of natural bromelain preparations. Intern Immunopharmacol. 
2005;5:783–93.
 24. Castell JV, Friedrich G, Kuhn CS, Poppe GE. Intestinal absorption of 
undegraded proteins in men: presence of bromelain in plasma after oral 
intake. Am J Physiol. 1997;273:139–46.
 25. Seifert J, Ganser R, Brendel W. Absorption of a proteolytic enzyme origi-
nating from plants out of the gastrointestinal tract into blood and lymph 
of rats. Z Gastroenterol. 1979;17:1–8.
 26. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin-
cytotoxicity. Cell Mol Life Sci. 2000;57:1229–35.
 27. Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte 
expression of cell surface molecules involved in cellular adhesion and 
activation. Clin Immunol. 2002;104:183–90.
 28. Bhui K, Tyagi S, Srivastava AK, Singh M, Roy P, Singh R, Shukla Y. Bromelain 
inhibits nuclear factor kappa-B translocation, driving human epidermoid 
carcinoma A431 and melanoma A375 cells through G2/M arrest to apop-
tosis. Mol Carcinog. 2012;51:231–43.
 29. Park MS, De Leon M, Devarajan P. Cisplatin induces apoptosis in LLC-
PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol. 
2002;13:858–65.
 30. Melendez-Zajgla J, Cruz E, Maldonado V, Espinoza AM. Mitochondrial 
changes during the apoptotic process of HeLa cells exposed to cisplatin. 
Biochem Mol Biol Int. 1999;47:765–71.
 31. Bhui K, Prasad S, George J, Shukla Y. Bromelain inhibits COX-2 expression 
by blocking the activation of MAPK regulated NF-kappa B against skin 
tumor-initiation triggering mitochondrial death pathway. Cancer Lett. 
2009;282:167–76.
 32. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, 
Gurbuxani S, Arrigo AP, Kroemer G, Solary E, Garrido C. Hsp27 negatively 
regulates cell death by interacting with cytochrome c. Nat Cell Biol. 
2000;2:645–52.
 33. Paul C, Manero F, Gonin S, Kretz-Remy C, Virot S, Arrigo AP. Hsp27 
as a negative regulator of cytochrome C release. Mol Cell Biol. 
2002;22:816–34.
 34. Wei MC, Zong WX, Cheng EHY, Lindsten T, Panoutsakopoulou V, Ross AJ, 
Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. Proapoptotic BAX 
and BAK: a requisite gateway to mitochondrial dysfunction and death. 
Science. 2001;292:727–30.
 35. Marzo I, Brenner C, Zamzami N, Jürgensmeier JM, Susin SA, Vieira HL, 
Prevost MC, Xie Z, Matsuyama S, Reed JC, Kroemer G. Bax and adenine 
nucleotide translocator cooperate in the mitochondrial control of apop-
tosis. Science. 1998;281:2027–31.
 36. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang 
X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mito-
chondria blocked. Science. 1997;275:1129–32.
 37. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of 
cytochrome c from mitochondria: a primary site for Bcl-2 regulation of 
apoptosis. Science. 1997;275:1132–6.
 38. Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, Daugas 
E, Geuskens M, Kroemer G. Bcl-2 inhibits the mitochondrial release of an 
apoptogenic protease. J Exp Med. 1996;184:1331–41.
 39. Gurbuxani S, Schmitt E, Cande C, Parcellier A, Hammann A, Daugas E, 
Kouranti I, Spahr C, Pance A, Kroemer G, Garrido C. Heat shock protein 70 
binding inhibits the nuclear import of apoptosis-inducing factor. Onco-
gene. 2003;22:6669–78.
 40. Ran R, Lu A, Zhang L, Tang Y, Zhu H, Xu H, Feng Y, Han C, Zhou G. Rigby 
Ac, Sharp FR: Hsp70 promotes TNF-mediated apoptosis by binding IKKγ 
and impairing NF-κB survival signaling. Genes Dev. 2004;18:1466–81.
 41. Feng X, Bonni S, Riabowol K. HSP70 induction by ING proteins sensitizes 
cells to tumor necrosis factor alpha receptor-mediated apoptosis. Mol 
Cell Biol. 2006;26:9244–55.
 42. Guzhova IV, Darieva ZA, Melo AR, Margulis BA. Major stress protein Hsp70 
interacts with NF-kB regulatory complex in human T-lymphoma cells. Cell 
Stress Chaperones. 1997;2:132–9.
